S&P 500   4,221.02 (+0.99%)
DOW   33,061.57 (+0.47%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
S&P 500   4,221.02 (+0.99%)
DOW   33,061.57 (+0.47%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
S&P 500   4,221.02 (+0.99%)
DOW   33,061.57 (+0.47%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
S&P 500   4,221.02 (+0.99%)
DOW   33,061.57 (+0.47%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
NASDAQ:SESN

Sesen Bio (SESN) Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$0.63
$12.99
52-Week Range
N/A
Volume
93,330 shs
Average Volume
1.07 million shs
Market Capitalization
$2.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

SESN vs. INSM, RVNC, MORF, SDGR, XENE, CORT, GLPG, NUVL, BBIO, and AKRO

Should you be buying Sesen Bio stock or one of its competitors? The main competitors of Sesen Bio include Insmed (INSM), Revance Therapeutics (RVNC), Morphic (MORF), Schrödinger (SDGR), Xenon Pharmaceuticals (XENE), Corcept Therapeutics (CORT), Galapagos (GLPG), Nuvalent (NUVL), BridgeBio Pharma (BBIO), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical preparations" industry.

Sesen Bio vs.

Insmed (NASDAQ:INSM) and Sesen Bio (NASDAQ:SESN) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, community ranking, earnings and institutional ownership.

Insmed presently has a consensus price target of $43.33, suggesting a potential upside of 125.23%.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Insmed
0 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
3.00
Sesen Bio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Insmed has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, Sesen Bio has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Sesen Bio has a net margin of 0.00% compared to Insmed's net margin of -212.33%. Sesen Bio's return on equity of 6.70% beat Insmed's return on equity.

Company Net Margins Return on Equity Return on Assets
Insmed -212.33% -3,789.32% -41.78%
Sesen Bio N/A 6.70% 5.41%

In the previous week, Insmed had 4 more articles in the media than Sesen Bio. MarketBeat recorded 4 mentions for Insmed and 0 mentions for Sesen Bio. Insmed's average media sentiment score of 0.81 beat Sesen Bio's score of 0.00 indicating that Insmed is being referred to more favorably in the media.

Company Overall Sentiment
Insmed Positive
Sesen Bio Neutral

Sesen Bio has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Sesen Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insmed$245.36 million10.70-$481.53 million-$4.27-4.51
Sesen Bio$40 million0.00-$19.88 million-$0.10N/A

92.8% of Insmed shares are held by institutional investors. Comparatively, 16.5% of Sesen Bio shares are held by institutional investors. 4.3% of Insmed shares are held by insiders. Comparatively, 3.2% of Sesen Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Insmed received 343 more outperform votes than Sesen Bio when rated by MarketBeat users. Likewise, 65.15% of users gave Insmed an outperform vote while only 59.43% of users gave Sesen Bio an outperform vote.

CompanyUnderperformOutperform
InsmedOutperform Votes
488
65.15%
Underperform Votes
261
34.85%
Sesen BioOutperform Votes
145
59.43%
Underperform Votes
99
40.57%

Summary

Insmed beats Sesen Bio on 10 of the 15 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SESN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SESN vs. The Competition

MetricSesen BioPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.56B$5.82B$4.54B$6.20B
Dividend YieldN/A2.74%2.42%6.15%
P/E Ratio-125.764.87100.6311.94
Price / SalesN/A326.473,636.6695.58
Price / Cash3.3920.1190.91108.26
Price / BookN/A5.435.157.27
Net Income-$19.88M$190.11M$117.81M$193.48M

Sesen Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INSM
Insmed
2.2009 of 5 stars
$18.69
-0.5%
$43.33
+131.9%
+1.1%$2.55B$245.36M-4.38373Analyst Upgrade
RVNC
Revance Therapeutics
2.1579 of 5 stars
$30.27
-0.6%
$42.36
+40.0%
+123.4%$2.54B$132.57M-6.57495Positive News
MORF
Morphic
1.9766 of 5 stars
$56.63
-1.1%
$70.33
+24.2%
+145.3%$2.58B$68.95M-34.53101
SDGR
Schrödinger
1.8346 of 5 stars
$34.47
-4.3%
$50.00
+45.1%
+29.5%$2.46B$197.07M265.17664High Trading Volume
XENE
Xenon Pharmaceuticals
2.2203 of 5 stars
$38.37
-4.3%
$51.50
+34.2%
+46.2%$2.44B$9.43M-16.54149Options Volume
CORT
Corcept Therapeutics
1.9781 of 5 stars
$23.05
-3.9%
$26.71
+15.9%
+12.7%$2.34B$401.86M28.11238Analyst Revision
GLPG
Galapagos
1.361 of 5 stars
$42.14
-1.7%
$45.37
+7.7%
-24.8%$2.78B$532.48M-15.161,338Analyst Report
NUVL
Nuvalent
1.0098 of 5 stars
$40.80
+1.4%
$44.50
+9.1%
+375.2%$2.32BN/A-23.7240Positive News
BBIO
BridgeBio Pharma
2.7801 of 5 stars
$13.54
-1.5%
$26.63
+96.6%
+100.9%$2.21B$77.78M-4.77576Short Interest ↓
AKRO
Akero Therapeutics
1.9345 of 5 stars
$43.89
-1.9%
$52.00
+18.5%
+416.0%$2.20BN/A-16.0833News Coverage

Related Companies and Tools

This page (NASDAQ:SESN) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -